NYU Winthrop Physician Paula Lester MD, FACP, CMD Authors COVID-19 Safety Recommendations

Aim To Reduce Deaths Among At-Risk Elderly in Nursing Homes

Seeking to address estimates that more than a third of COVID-19 deaths nationally have occurred in nursing homes and long-term care facilities—more than 38,000 – the American Medical Directors Association published recommendations for reducing the spread of the pandemic virus among residents and staff.

Among the recommendations were the creation of COVID-specific units, screenings of residents twice daily, discontinuing of drug delivery modes (e.g. nebulizers) that might spread the virus, and reviews with patients and families of do-not-intubate and do-not-hospitalize advance directives.

“The scope and speed of the COVID-19 pandemic brought continual changes in healthcare protocols as providers learned more about the disease’s transmission,” said Paula Lester, MD, FACP, CMD, a geriatrician at NYU Winthrop Hospital and the corresponding author of the consensus recommendations, which were recently published online in Journal of American Medical Directors Association (JAMDA).

“The time has come to consolidate our learnings as a field in terms of caring for at-risky elderly and implement uniform, best practices, especially as we prepare for a potential second wave of infections in the coming months, as well as for future pandemics,” adds Lester, who along with her co-authors, serves as a skilled nursing facility (SNF) certified medical director.

Recommended protocols for facility staff also include COVID testing on a serial basis—three tests one-week apart—to enable identification of newly infected staff. Also recommended is to have staff assigned to specific units to permit easier contact tracing in the event of COVID cases, and to have staff that are assigned to COVID-19 units not work elsewhere in the facility.

The report also states that the authors “do not support the mandatory admission of COVID-19 patients from hospitals to nursing homes as it may force unprepared facilities to provide care to COVID patients without the necessary resources or precautions.”

The consensus guidelines in the report – titled “Policy Recommendations Regarding Skilled Nursing Facility Management of COVID-19: Lessons From New York State” – are endorsed by the Executive Board of the New York Medical Directors Association and the Board of the Metropolitan Area Geriatrics Society. The authors noted, however, that the suggestions in the report should not take precedence over local Department of Health or Centers for Disease Control recommendations.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”